Browsing Tag
enGene Holdings Inc.
1 post
enGene (Nasdaq: ENGN) secures credit facility from Hercules Capital to support bladder cancer gene therapy and 2026 FDA filing
enGene secures $125M debt facility from Hercules Capital to fund detalimogene bladder cancer gene therapy. Find out what this means for its 2026 FDA filing.